Tue, May 13, 8:47 PM (30 days ago)
**Lyell Immunopharma, Inc. (LYEL) Q1 2025 Financial Summary** **Financial Health:** - **Revenue:** $7,000 (up $4,000 from Q1 2024) - **Operating Expenses:** $57,374,000 (up $1,796,000 from Q1 2024) - **Net Loss:** $52,195,000 (down $8,472,000 from Q1 2024) - **Cash Flow:** Positive cash flow from investing activities of $69,466,000 **Performance Metrics:** - **Research & Development (R&D) Expenses:** $43,447,000 (up $273,000 from Q1 2024) - **Personnel Costs:** $19,615,000 (up $3,141,000) - **Facilities & Technology:** $12,082,000 (down $815,000) - **Research Activities:** $11,750,000 (down $1,528,000) - **General & Administrative (G&A) Expenses:** $14,046,000 (up $552,000 from Q1 2024) - **Personnel Costs:** $9,071,000 (up $600,000) - **Interest Income:** $3,862,000 (down $2,957,000 from Q1 2024) - **Other Income:** $1,310,000 (up $220,000 from Q1 2024) **Profit Margins:** - **Operating Margin:** -98.8% (improved from -99.7% in Q1 2024) - **Net Margin:** -745.6% (improved from -982.1% in Q1 2024) **Cash Flow:** - **Operating Cash Flow:** -$54,738,000 (improved from -$42,016,000 in Q1 2024) - **Investing Cash Flow:** $69,466,000 (up from $21,994,000 in Q1 2024) - **Financing Cash Flow:** $1,000 (up from -$19,995,000 in Q1 2024) **Earnings Changes:** - **Net Loss per Share:** -$0.18 (improved from -$0.24 in Q1 2024) **Quarterly Performance Discussion:** - **Revenue Growth:** Minimal revenue from collaborations and strategic alliances. - **Expense Management:** Increased personnel costs in R&D and G&A due to workforce expansion and severance expenses. - **Cash Flow:** Positive investing cash flow driven by maturities and purchases of marketable securities. **Trends:** - **R&D Focus:** Continued investment in LYL314 and preclinical programs. - **Operational Efficiency:** Efforts to optimize manufacturing and reduce costs. **Uncertainties:** - **Regulatory Approval:** Uncertainty surrounding the regulatory pathway for LYL314. - **Market Competition:** Intensifying competition in the CAR T-cell therapy space. **Future Operations Impact:** - **Clinical Trials:** Ongoing Phase 1/2 trial for LYL314 with plans for pivotal trials in 2025. - **Manufacturing:** Transition to LyFE Manufacturing Center for LYL314 production.